{"transactions":[{"id":930164,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":68715,"kind":"person","name":"Levin Ilan","position":1,"cik":"0001849189","reported_name":"Levin Ilan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":68716,"kind":"organization","name":"Moringa Sponsor, LP","position":2,"cik":"0001849192","reported_name":"Moringa Sponsor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2026-01-27T16:03:18.000Z","date":"2025-08-07","kind":"other","planned":false,"acquired":false,"shares":935,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Moringa Sponsor, LP."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP."},{"field":"shares","element":"transactionShares","label":"F7","text":"The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F7","text":"The number of warrants to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those warrants has been adjusted proportionately upwards, to reflect the 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and the 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein."}],"balance_after":372,"derivative":{"exercise_price":1552.5,"exercise_date":"2024-09-14","expiration_date":"2029-08-15","underlying":"Ordinary Shares","underlying_shares":935},"source":{"system":"sec-edgar","filing":"0001178913-26-000228","document":"zk2634255.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000228/zk2634255.xml","form_type":"4"}},{"id":930163,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":68715,"kind":"person","name":"Levin Ilan","position":1,"cik":"0001849189","reported_name":"Levin Ilan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":68716,"kind":"organization","name":"Moringa Sponsor, LP","position":2,"cik":"0001849192","reported_name":"Moringa Sponsor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-27T16:03:18.000Z","date":"2025-09-15","kind":"grant","planned":false,"acquired":true,"shares":450000,"price":4,"value":1800000.0,"ownership":{"direct":false,"nature":"By Moringa Sponsor, LP."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares."},{"field":"shares","element":"transactionShares","label":"F4","text":"The transaction reported in this row was the issuance of 450,000 ordinary shares to Moringa Sponsor, LP. upon conversion of $1,800,000 of the outstanding principal amount under the convertible promissory note, dated August 15, 2024, issued by the Issuer to Moringa Sponsor, LP., which is convertible based on the market price of the ordinary shares or the price at which the Issuer sells ordinary shares in an equity financing from time to time. The conversion price was $4.00 per share and the related issuance was approved by the Issuer's board of directors. The Reporting Persons expressly dispute the validity of the subject issuance and do not concede beneficial ownership of those 450,000 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein."}],"balance_after":456970,"source":{"system":"sec-edgar","filing":"0001178913-26-000228","document":"zk2634255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000228/zk2634255.xml","form_type":"4"}},{"id":930162,"issuer":{"id":8506,"kind":"organization","name":"Silexion Therapeutics Corp"},"owners":[{"id":68715,"kind":"person","name":"Levin Ilan","position":1,"cik":"0001849189","reported_name":"Levin Ilan","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":68716,"kind":"organization","name":"Moringa Sponsor, LP","position":2,"cik":"0001849192","reported_name":"Moringa Sponsor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-27T16:03:18.000Z","date":"2025-08-07","kind":"other","planned":false,"acquired":false,"shares":5550,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Moringa Sponsor, LP."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported in this row was the pro rata distribution, for no consideration, by Moringa Sponsor, LP. to certain of its limited partners, of ordinary shares or warrants (as applicable) of the Issuer in proportion to those limited partners' respective pro rata interests in the equity of Moringa Sponsor, LP."},{"field":"shares","element":"transactionShares","label":"F2","text":"The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The numbers of ordinary shares reported in this Form 4 reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Ilan Levin is the sole equity owner and serves as the sole director of Moringa Partners Ltd., a company that is the sole general partner of Moringa Sponsor, LP. (which holds the subject ordinary shares or warrants, as applicable). As a result of that relationship, Mr. Levin possesses sole voting and investment authority with respect to the subject ordinary shares or warrants. The limited partnership interests of Moringa Sponsor, LP, are held by various individuals and entities. Ilan Levin disclaims beneficial ownership of the subject ordinary shares or warrants (as applicable) except to the extent of his indirect pecuniary interest therein."}],"balance_after":6970,"source":{"system":"sec-edgar","filing":"0001178913-26-000228","document":"zk2634255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326000228/zk2634255.xml","form_type":"4"}},{"id":2809203,"issuer":{"id":110260,"kind":"organization","name":"Moringa Acquisition Corp","symbol":"MACA"},"owners":[{"id":68716,"kind":"organization","name":"Moringa Sponsor, LP","position":1,"cik":"0001849192","reported_name":"Moringa Sponsor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141816,"kind":"organization","name":"Moringa Sponsor US L.P.","position":2,"cik":"0001849191","reported_name":"Moringa Sponsor US L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":68715,"kind":"person","name":"Levin Ilan","position":3,"cik":"0001849189","reported_name":"Levin Ilan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Units composed of 1 Class A ordinary share & 0.5 warrants","published_at":"2021-03-04T15:16:41.000Z","date":"2021-03-03","kind":"purchase","acquired":true,"shares":27857,"price":10,"value":278570.0,"ownership":{"direct":false,"nature":"By Moringa Sponsor US L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer."},{"field":"kind","element":"transactionCoding","label":"F4","text":"Moringa Sponsor US L.P. purchased, in a private placement concurrent with an additional closing under the Issuer's initial public offering, 27,857 units, at a purchase price of $10.00 per unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the \"Sponsor Entities\"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein."}],"balance_after":352857,"source":{"system":"sec-edgar","filing":"0001213900-21-013421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1849189/000121390021013421/ownership.xml","form_type":"4"}},{"id":2809202,"issuer":{"id":110260,"kind":"organization","name":"Moringa Acquisition Corp","symbol":"MACA"},"owners":[{"id":68716,"kind":"organization","name":"Moringa Sponsor, LP","position":1,"cik":"0001849192","reported_name":"Moringa Sponsor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":141816,"kind":"organization","name":"Moringa Sponsor US L.P.","position":2,"cik":"0001849191","reported_name":"Moringa Sponsor US L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":68715,"kind":"person","name":"Levin Ilan","position":3,"cik":"0001849189","reported_name":"Levin Ilan","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Units composed of 1 Class A ordinary share & 0.5 warrants","published_at":"2021-03-04T15:16:41.000Z","date":"2021-02-19","kind":"purchase","acquired":true,"shares":325000,"price":10,"value":3250000.0,"ownership":{"direct":false,"nature":"By Moringa Sponsor US L.P."},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Class A ordinary shares and warrants comprising the units are expected to begin separate trading on the 90th day following the date of the prospectus for the Issuer's initial public offering, unless the representative of the underwriters for that offering allows earlier separate trading, which would be publicly announced by the Issuer."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Moringa Sponsor US L.P. purchased, in a private placement concurrent with the initial closing under the Issuer's initial public offering, 325,000 units, at a purchase price of $10.00 per unit."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Moringa Sponsor US L.P. (which purchased the units and also holds the Class A ordinary shares reported herein) is a wholly-owned subsidiary of Moringa Sponsor, LP (those two entities, the \"Sponsor Entities\"). Mr. Ilan Levin serves as the sole director of, and is the sole equity owner of, the sole general partner of the Sponsor Entities and therefore possesses sole voting and investment authority with respect to the securities reported in this line. The limited partnership interests of Moringa Sponsor, LP are held by various individuals and entities. Mr. Levin disclaims beneficial ownership of the securities reported herein other than to the extent of his indirect pecuniary interest therein."}],"balance_after":325000,"source":{"system":"sec-edgar","filing":"0001213900-21-013421","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1849189/000121390021013421/ownership.xml","form_type":"4"}}]}